1-20 of 71
Carol Moreno
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Carol Moreno, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Qianya Qi, Emma Smith, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (Supplement 1): 634.
https://doi.org/10.1182/blood-2023-177713
Published: 2023
Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Christelle Ferra, María José Terol, Juan Marquet Palomanes, Angel Ramírez Payer, Carol Moreno, Santiago Osorio, Fátima De la Cruz, Jose A. Garcia-Marco, Macarena Ortiz, Eduardo Rios Herranz, Laura Magnano, Sandra Iraheta, Jose Manuel Puerta, Javier de la Serna, Alicia Smucler, Jose Maria Arguiñano, Javier Loscertales, Begoña Muiña, Rubén Fernández, Tomas García, José A. Márquez, Ana Muntañola Prat, Ernesto Perez Persona, Lucrecia Yáñez, Manuel Pérez-Encinas, Marcos González Díaz, Gonzalo Caballero, María Angeles Andreu, Rafael Andreu, Ana Ruiz-Zorrilla, Diana Moreno, Patricia Baltasar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9908–9910.
https://doi.org/10.1182/blood-2022-162186
Published: 2022
Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianaya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 228–230.
https://doi.org/10.1182/blood-2022-156070
Published: 2022
Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Clinical Trials & Observations
Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia
Journal: Blood
Blood (2022) 139 (22): 3278–3289.
https://doi.org/10.1182/blood.2021014488
Published: 2022
Includes: Supplemental data
Journal Articles

MRD in CLL: some answers, many questions

Carol Moreno, Alba Mora
Journal: Blood
Blood (2021) 138 (26): 2746–2747.
https://doi.org/10.1182/blood.2021013435
Published: 2021
Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Tahla Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir I. Vorobyev, Munchi Yagci, Loic Ysebaert, Qianaya Qi, Andrew Steele, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 70.
https://doi.org/10.1182/blood-2021-148666
Published: 2021
Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Patricia Baltasar, María José Terol, Juan Marquet Palomanes, Angel Ramírez Payer, Carol Moreno, Santiago Osorio, Fátima De la Cruz, Jose A. Garcia-Marco, Sr., Macarena Ortiz, Eduardo Ríos Herranz, Laura Magnano, Sandra Iraheta, Jose Manuel Puerta, Javier de la Serna, Alicia Smucler Simonovich, Jose Maria Arguiñano, Javier Loscertales, Begoña Muiña, Ruben Fernandez, Tomas García, José A. Márquez, Ana Muntañola Prat, Ernesto Pérez Persona, Lucrecia Yáñez, Manuel Pérez-Encinas, Marcos González Díaz, Gonzalo Caballero, María Angeles Andreu, Rafael Andreu, Ana Ruiz-Zorrilla, Diana Moreno, Christelle Ferrà
Journal: Blood
Blood (2021) 138 (Supplement 1): 1561.
https://doi.org/10.1182/blood-2021-147685
Published: 2021
Journal Articles

Autoimmune cytopenia and CLL ride together

Carol Moreno
Journal: Blood
Blood (2021) 137 (25): 3464–3465.
https://doi.org/10.1182/blood.2021010944
Published: 2021
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, MD PhD, Constantine S. Tam, MD, John N. Allan, MD, Tanya Siddiqi, MD, Thomas J. Kipps, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Sharon Jackson, MD, Carol Moreno, MD PhD, Ryan Jacobs, MD, John M. Pagel, MD PhD, Ian W. Flinn, MD PhD, Cathy Zhou, MS, Edith Szafer-Glusman, PhD, Joi Ninomoto, PharmD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134446
Published: 2020
Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134437
Published: 2020
Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-134386
Published: 2020
Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134431
Published: 2020
Journal Articles

Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

Silvia Ramos Campoy, Anna Puiggros, PhD, Silvia Bea, PhD, Sandrine Bougeon, Maria Jose Larrayoz, PhD, Guillem Clot, Dolors Costa, MD, Gian Matteo Rigolin, MD, Margarita Ortega, Laura Blanco, Rosa Collado, MD, Rocio N Salgado, PhD, María-Dolores García-Malo, MD, Andrea Campeny, Alberto Valiente, Ferran Nadeu, BSc, MSc, Julio Delgado, Tycho Baumann, Idoya Ancín, Marco Antonio Moro García, Eva Gimeno, MD PhD, Carol Moreno, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Gonzalo Blanco, PhD, Maria Jose Calasanz, PhD BSc, Antonio Cuneo, MD, Claudia Haferlach, MD, Jacqueline Schoumans, PhD, Blanca Espinet, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4287.
https://doi.org/10.1182/blood-2019-126557
Published: 2019
Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Pau Abrisqueta, MD PhD, Eva González-Barca, MD PhD, Christelle M Ferra, Eduardo Ríos Herranz, MD, Margarita Fernandez, MD, Julio Delgado, MD, Rafael Andreu, MD, Jose Angel Hernandez-Rivas, MD PhD, Maria Jose Terol, Marcos González, Patricia Baltasar Tello, MD, Javier de la Serna, MD PhD, Angel Ramirez Payer, Carmen Ballester, MD, Carol Moreno, MD PhD, Jose A. Garcia-Marco, MD PhD, Raul Cordoba, MD PhD, Lucrecia Yanez San Segundo, MD PhD, Luis Felipe Casado Montero, MD, Francesc Bosch, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4296.
https://doi.org/10.1182/blood-2019-128470
Published: 2019
Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Clinical Trials & Observations
John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown
Journal: Blood
Blood (2019) 133 (19): 2031–2042.
https://doi.org/10.1182/blood-2018-08-870238
Published: 2019
Includes: Supplemental data
Journal Articles

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

Jennifer R. Brown, MD PhD, Ian W. Flinn, MD PhD, Matthew S. Davids, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, Zsolt Nagy, MD PhD, Julio Delgado, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Ulrich Jaeger, MD, Paolo Ghia, MD PhD, Stephan Stilgenbauer, Carol Moreno, MD PhD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Kam Sprott, PhD, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Florence Cymbalista, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1856.
https://doi.org/10.1182/blood-2018-99-114251
Published: 2018
Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 691.
https://doi.org/10.1182/blood-2018-99-111370
Published: 2018
Journal Articles

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Alessandra Tedeschi, MD, Richard Greil, MD, Fatih Demirkan, MD, Tadeusz Robak, MD PhD, Carol Moreno, MD PhD, Paul Barr, MD, Bertrand Anz, MD, David Simpson, MBChB, FRACP, FRCPA, Gianluca Gaidano, MD PhD, Osnat Bairey, MD, Don Stevens, MD, Devinder Gill, MD MRCP, FRCPath, Ian W. Flinn, MD PhD, Thomas J. Kipps, MD PhD, Jan A. Burger, MD PhD, Jennifer Lin, MA, MS, Thomas Webb, MSc, Viktor Fedorov, MD, Lori Styles, MD, John G. Gribben
Journal: Blood
Blood (2018) 132 (Supplement 1): 5565.
https://doi.org/10.1182/blood-2018-99-111369
Published: 2018
Journal Articles

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

Clinical Trials & Observations
Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer, Emili Montserrat
Journal: Blood
Blood (2018) 132 (9): 892–902.
https://doi.org/10.1182/blood-2018-01-826008
Published: 2018
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic Leukemia: Results of the Gimema-Eric LLC1315 Study

Antonio Cuneo, MD, Gian Matteo Rigolin, Alfonso Piciocchi, Carol Moreno, MD, Atto Billio, Agostino Cortelezzi, Prof, Piero Galieni, MD, Luca Laurenti, Francesca Romana Mauro, Stefano Molica, MD, Massimo Gentile, MD, Marco Montillo, MD, Livio Trentin, MD, Angeles Medina Perez, Marta Coscia, Gerardo Musuraca, MD, Lucia Farina, Alfredo Rivas-Delgado, MD, Ester Maria Orlandi, MD, Stefania Ciolli, MD, Carlo Visco, Michele Pizzuti, MD, Roberto Marasca, Monia Marchetti, MD, Francesca Re, Marcos González, MD, Annalisa Chiarenza, MD PhD, Vittorio Meneghini, Fiorella Ilariucci, Gianluca Gaidano, MD PhD, Marco Vignetti, Javier De la Serna, MD, Robin Foa, MD, George A Follows, MD PhD, Paolo Ghia
Journal: Blood
Blood (2017) 130 (Supplement 1): 4330.
https://doi.org/10.1182/blood.V130.Suppl_1.4330.4330
Published: 2017